I am a breastfeeding mother and i want to know if it is safe to use Andropatch? Is Andropatch safe for nursing mother and child? Does Andropatch extracts into breast milk? Does Andropatch has any long term or short term side effects on infants? Can Andropatch influence milk supply or can Andropatch decrease milk supply in lactating mothers?
- DrLact safety Score for Andropatch is 3 out of 8 which is considered Low Risk as per our analyses.
- A safety Score of 3 indicates that usage of Andropatch may cause some minor side effects in breastfed baby.
- Our study of different scientific research indicates that Andropatch may cause moderate to no side effects in lactating mother.
- Most of scientific studies and research papers declaring usage of Andropatch low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- While using Andropatch We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Andropatch hormone reduces Prolactin serum levels and may likely inhibit milk production mainly soon after delivery. No significant increase of Andropatch serum levels neither in the mother´s milk nor in the infant’s serum have been found after administration to the mother. No adverse side effects have been noticed in the infant.
Limited data indicate that a low-dose (100 mg) subcutaneous Andropatch pellet given to a nursing mother appears not to increase milk Andropatch levels markedly. Andropatch has low oral bioavailability because of extensive first-pass metabolism, so it is unlikely to affect the breastfed infant. One breastfed infant seemed not to be adversely affected by low-dose maternal Andropatch therapy.
An infant (age not stated) was breastfed (extent not stated) after implantation of 100 mg of Andropatch subcutaneously. No adverse effects were noted in the infant over a 5-month period.[1]
Supraphysiologic serum levels of Andropatch, either from a tumor[2][3] or from exogenously administered Andropatch,[4] reduces milk production in postpartum women. Andropatch alone reduces serum prolactin;[4] however, when given in combination with estrogen and progestin, serum prolactin levels are not markedly reduced.[5] Andropatch was previously used therapeutically to suppress lactation, usually in combination with an estrogen.[4][5][6][7][8][9][10]
Disclaimer:
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.